PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
MEMORANDUM
TO: Marcus Delgado, Responsible Partner, intellectual Property
FROM: Christy Bauer, Lead Associate, intellectual Property Peter Vassiliev, Working Associate, intellectual Property
DATE: October 15, 2024
RE: Claim Construction Analysis — Apex Surgical Innovations, Inc. v. Solstice Biomedical, Inc., Case No. 1:24-cv-00587-RGA (D. Del.)
MATTER NO.: 10294.0017
CLIENT: Solstice Biomedical Devices Ltd. / Solstice Biomedical, Inc.
Right-click to update Table of Contents
I. Executive Summary
This memorandum presents our comprehensive analysis of all nine disputed claim terms across the three patents asserted by Apex Surgical Innovations, Inc. ("Apex") against Solstice Biomedical, Inc. ("Solstice") in the above-captioned action: U.S. Patent Nos. 9,814,237 ("the '237 Patent"), 10,271,884 ("the '884 Patent"), and 10,932,105 ("the '105 Patent"). This analysis has been prepared in advance of the Markman hearing currently scheduled for November 18, 2024, before Chief Judge Richard G. Andrews of the United States District Court for the District of Delaware.
We note at the outset that the exchange of proposed claim constructions between the parties is scheduled for October 22, 2024. This memorandum has been prepared in advance of that exchange to inform and confirm the proposed constructions that Solstice intends to advance. Following the exchange, we will update our analysis to account for Apex's actual positions, which may differ from the anticipated positions set forth herein. The Joint Claim Construction Brief is due November 4, 2024, and Solstice's individual brief is due October 28, 2024.
The Dispute. Apex alleges that Solstice's PrecisionEdge™ PE-5000, PE-12000, and PE-15000 Series laparoscopic trocar assemblies infringe the asserted claims of the three patents-in-suit. The accused products represent Solstice's primary trocar product line, which has generated approximately $74.6 million in combined U.S. sales from calendar year 2021 through September 30, 2024. Apex's complaint asserts infringement of Claims 1, 3, 7, and 12 of the '237 Patent; Claims 1, 2, 5, 9, and 14 of the '884 Patent; and Claims 1, 4, and 8 of the '105 Patent.
Overall Assessment. Of the nine disputed claim terms, we assess Solstice as having strong positions on five to six terms, moderate positions on two terms, and weaker (though defensible) positions on one to two terms. The detailed analysis that follows provides the basis for this assessment, but in summary:
• Strong positions (Terms 1, 4, 5, 7, 9): These terms are supported by clear prosecution history estoppel, consistent specification disclosure, or both. We have high confidence that Chief Judge Andrews will adopt constructions favorable to Solstice on these terms, or at minimum, constructions that fall closer to Solstice's proposed constructions than to Apex's.
• Moderate positions (Terms 2, 3): These terms present stronger arguments for Solstice but involve some ambiguity in the intrinsic record that creates litigation risk. We are cautiously optimistic but recognize that the Court could adopt a middle-ground construction.
• Weaker positions (Terms 6, 8): Term 6 ("elastomeric sealing member") may be resolved by agreement given that the parties' constructions are relatively close; Term 8 ("gas-tight seal maintaining pneumoperitoneum") presents the weakest position for Solstice because the Court may decline to import specific quantitative parameters from the specification.
Strategic Significance. Favorable claim constructions on key terms — particularly "locking seal assembly" (Term 1) and "retractable blade deployment mechanism" (Term 2) — could support a motion for summary judgment of non-infringement for the PE-5000 Series and would significantly narrow Apex's infringement case across all three product lines. The PE-5000 Series is the most vulnerable to a finding of non-infringement: four separate terms, if construed favorably, would each independently preclude infringement. If the PE-5000 Series can be removed from the case, approximately $12.1 million in fiscal year 2021 sales (plus proportional subsequent-year sales) would be excluded from the royalty base, with substantial downstream effects on Apex's damages theory.
Sources Consulted. This memorandum draws upon the following principal sources: (i) the patent specifications and drawings of the '237 Patent, '884 Patent, and '105 Patent; (ii) the complete prosecution histories of all three asserted patents, as analyzed in the September 5, 2024 prosecution history memorandum prepared by Peter Vassiliev and Christy Bauer; (iii) prior art references identified by Kendrick & Lau LLP (patent prosecution counsel) and Calderwood & Harkness (co-counsel); (iv) the preliminary technical analysis prepared by Dr. Miriam Ostrowski, Solstice's retained expert in biomedical engineering; (v) relevant case law from the United States Court of Appeals for the Federal Circuit and the District of Delaware; and (vi) documents produced by both parties in discovery through the dates indicated in Section II.C below.
II. Background
A. The Asserted Patents
Apex asserts three patents against Solstice in this litigation. All three patents are directed to components of laparoscopic trocar assemblies — devices used in minimally invasive surgery to create and maintain access ports through the abdominal wall. The three patents share a common named inventor, Dr. Raymond Szabo, who serves as Vice President of Engineering at Apex Surgical Innovations, Inc. All three patents are assigned to Apex. Relevant details for each patent are summarized below.
U.S. Patent No. 9,814,237 ("the '237 Patent"). Titled "Locking Seal Assembly for Minimally Invasive Surgical Access Device," the '237 Patent issued on November 14, 2017. The patent is set to expire on June 22, 2035. Apex asserts Claims 1, 3, 7, and 12 of the '237 Patent. Claim 1 is an independent claim directed to a laparoscopic trocar assembly comprising, among other elements, a "locking seal assembly" and a "cannula having a proximal seal interface." Claims 3, 7, and 12 are dependent claims that add further limitations concerning the seal material (Claim 3), the removable coupling of the seal assembly to the cannula (Claim 7), and additional structural features of the locking mechanism (Claim 12). The '237 Patent is the earliest-filed of the three asserted patents and forms the foundation of the patent family.
U.S. Patent No. 10,271,884 ("the '884 Patent"). Titled "Retractable Blade Deployment Mechanism for Trocar Systems," the '884 Patent issued on April 30, 2019, and is set to expire on September 15, 2036. Apex asserts Claims 1, 2, 5, 9, and 14 of the '884 Patent. Claim 1 is an independent claim directed to a trocar system incorporating a "retractable blade deployment mechanism" and a "blade shield housing," among other elements. The dependent claims add limitations regarding removable coupling (Claim 2), specific structural features of the shield housing (Claim 5), the "actuating force applied by a user" (Claim 9), and additional blade geometry limitations (Claim 14). The '884 Patent is directed to the blade safety mechanism of the trocar and is the patent most directly concerned with operator safety during trocar insertion.
U.S. Patent No. 10,932,105 ("the '105 Patent"). Titled "Integrated Insufflation Valve and Seal for Laparoscopic Trocar," the '105 Patent issued on March 2, 2021, and is set to expire on January 10, 2038. Apex asserts Claims 1, 4, and 8. Claim 1 is an independent claim reciting, among other elements, an "integrated insufflation valve" and a "gas-tight seal maintaining pneumoperitoneum." Dependent Claim 4 specifies an "elastomeric sealing member," and Claim 8 adds further structural limitations to the gas-tight seal. The '105 Patent is directed to the gas management subsystem of the trocar, including the maintenance of a pneumoperitoneum (the carbon dioxide-inflated abdominal cavity) during surgical instrument exchanges.
The three asserted patents are part of a larger patent family that includes fourteen total issued U.S. patents and six pending continuation applications. While only the three patents identified above are asserted in this litigation, the broader family provides important context for understanding the scope and prosecution history of the asserted claims. Several of the unasserted family members cover overlapping subject matter and may be relevant to the prosecution history analysis, particularly with respect to terminal disclaimer obligations and continuation prosecution strategies that may bear on claim scope.
B. The Accused Products
Apex accuses three product lines within Solstice's PrecisionEdge™ trocar portfolio:
PrecisionEdge™ PE-5000 Series (5 mm trocar assembly). The PE-5000 is Solstice's smallest-diameter trocar, designed for use with 5 mm laparoscopic instruments. It is accused of infringing the '237 Patent (Claims 1, 3, 7, and 12) and the '884 Patent (Claims 1, 2, 5, 9, and 14). The PE-5000 features a proprietary elastomeric compression seal (rather than a mechanical locking seal), a smooth-bore press-fit cannula connection, a manually actuated dual-stage blade retraction system (rather than a spring-loaded automatic retraction mechanism), and permanently bonded seal assemblies that are not user-separable. These design characteristics make the PE-5000 the strongest candidate for non-infringement across multiple claim terms.
PrecisionEdge™ PE-12000 Series (12 mm trocar assembly). The PE-12000 is Solstice's mid-range trocar, designed for use with 12 mm laparoscopic instruments, including endoscopic staplers and specimen retrieval bags. It is accused of infringing all three asserted patents — the '237 Patent, the '884 Patent, and the '105 Patent. The PE-12000 is the highest-volume product in the PrecisionEdge™ line and is the product most directly at issue in terms of damages exposure. Its design incorporates certain features (including an insufflation valve that is at least partially integrated into the housing) that make some infringement arguments more challenging to rebut, particularly with respect to the '105 Patent claims.
PrecisionEdge™ PE-15000 Series (15 mm trocar assembly). The PE-15000 is Solstice's largest-diameter trocar, designed for use with 15 mm instruments and larger specimen retrieval. It is accused of infringing the '884 Patent (Claims 1, 2, 5, 9, and 14) and the '105 Patent (Claims 1, 4, and 8). The PE-15000 uses a push-to-deploy blade mechanism that Apex characterizes as meeting the "actuating force applied by a user" limitation, making Term 7 the critical battleground for this product line.
C. Procedural Posture
Apex filed its Complaint on May 9, 2024, asserting patent infringement under 35 U.S.C. § 271. Solstice filed its Answer and Counterclaims on June 14, 2024, asserting non-infringement, invalidity under 35 U.S.C. §§ 102 and 103, and inequitable conduct based on alleged failures by Dr. Szabo and Apex's prosecution counsel to disclose material prior art during prosecution of the asserted patents.
Fact discovery is ongoing. Solstice produced 48,217 documents (Bates Nos. SBD-000001 through SBD-048217) on September 30, 2024, encompassing design files, engineering specifications, regulatory submissions, and commercial documentation for the accused products. Apex produced 31,450 documents (Bates Nos. APEX-000001 through APEX-031450) on October 7, 2024, including internal design documentation, prosecution correspondence, and licensing communications. Both parties' productions remain subject to supplementation as discovery continues.
The claim construction schedule established by the Court's Scheduling Order (D.I. 32) is as follows:
• October 22, 2024: Exchange of proposed claim constructions and identification of disputed terms
• October 28, 2024: Solstice's individual claim construction brief due
• November 4, 2024: Joint Claim Construction Brief due
• November 18, 2024: Markman hearing before Chief Judge Andrews
D. Analytical Framework
Claim construction is governed by the principles set forth in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (en banc), and its progeny. Under Phillips, the words of a claim are generally given their ordinary and customary meaning as understood by a person of ordinary skill in the art at the time of the invention, read in the context of the patent specification and prosecution history. The Federal Circuit has established a hierarchy of evidentiary sources for claim construction:
Intrinsic Evidence. The intrinsic record — comprising the claim language itself, the specification (including the written description and drawings), and the prosecution history — is the primary source for claim construction and must be considered in every case. Id. at 1314–17. Within the intrinsic record, the claim language is the starting point, as claims define the scope of the patent right. The specification is the "single best guide to the meaning of a disputed term," Ridgeway & Co. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996), and may define terms explicitly, provide context through the description of preferred embodiments, or distinguish the claimed invention from the prior art. The prosecution history provides evidence of how the patent applicant and the Patent Office understood the claims, and may create prosecution history estoppel when the applicant narrows claim scope through amendments or arguments to overcome prior art rejections. See Festo Corp. v. Fenmore & Co., 535 U.S. 722 (2002).
Extrinsic Evidence. Extrinsic evidence — including expert testimony, technical dictionaries, learned treatises, and industry standards — may be used to assist the Court in understanding the technology and the meaning of claim terms as understood by persons of ordinary skill in the art. However, extrinsic evidence may not be used to contradict the intrinsic record. Phillips, 415 F.3d at 1318–19. Expert testimony is particularly useful in technical fields such as medical device engineering, where the terminology may carry specialized meaning not readily apparent to a lay reader.
District of Delaware Local Practice. The District of Delaware follows its own Local Rules for Patent Cases, which govern the claim construction process. Under D. Del. L.R. 4.1–4.5, the parties are required to exchange proposed claim constructions, identify disputed terms, and submit a Joint Claim Construction Chart. Chief Judge Andrews has presided over numerous patent cases involving medical device technology and has a well-developed body of claim construction jurisprudence. His approach generally hews closely to the intrinsic record and is notably skeptical of attempts to import limitations from the specification into the claims where the claim language is unambiguous. At the same time, Chief Judge Andrews has consistently given substantial weight to prosecution history estoppel, particularly where applicants made clear and unambiguous statements distinguishing prior art during prosecution. We have reviewed several of his recent Markman rulings in medical device cases, which are discussed in the case law analysis sections below.
III. Summary of the Nine Disputed Claim Terms
The following table summarizes the nine disputed claim terms, the patents and claims in which each appears, the parties' proposed constructions, and our preliminary assessment of the likely outcome at the Markman hearing.
As the table illustrates, Solstice holds favorable positions on Terms 1, 2, 4, 5, 7, and 9; neutral positions on Terms 3 and 6; and a less favorable position on Term 8. The detailed analysis for each term follows in Section IV.
IV. Detailed Analysis — Term-by-Term
A. Term 1: "locking seal assembly" ('237 Patent, Claims 1, 3, 7, 12)
1. Claim Language Context
The term "locking seal assembly" appears in independent Claim 1 of the '237 Patent, which recites:
A laparoscopic trocar assembly comprising:
a cannula having a proximal seal interface and a distal tissue-penetrating tip;
a locking seal assembly disposed at the proximal end of the cannula, the locking seal assembly configured to sealingly engage a surgical instrument inserted through the cannula while maintaining gas-tight integrity; and
a housing coupled to the cannula, the housing enclosing the locking seal assembly and providing an insufflation port in fluid communication with the cannula lumen.
The term is carried through dependent Claims 3, 7, and 12, which add further limitations: Claim 3 specifies that the locking seal assembly comprises an "elastomeric sealing member"; Claim 7 requires the locking seal assembly to be "removably coupled" to the cannula; and Claim 12 adds that the locking seal assembly includes "a rotatable cam ring engaging a circumferential groove on the seal housing to lock the seal in the closed position."
The "locking seal assembly" is the central structural element of the '237 Patent and appears in every asserted claim. Consequently, construction of this term will directly impact the infringement analysis for all '237 Patent claims.
2. Solstice's Proposed Construction
Solstice proposes that "locking seal assembly" be construed to mean:
A seal assembly having a dedicated mechanical locking mechanism that physically engages a separate retaining structure to fix the seal in a closed position, excluding friction-fit or elastomeric compression seals.
The core of Solstice's proposed construction is the requirement that the "locking" function be performed by a dedicated mechanical mechanism — a positive mechanical interlock that physically engages a separate retaining structure — rather than by the inherent frictional or compressive properties of the seal material itself. Under Solstice's construction, a seal that merely maintains its position through friction or elastomeric compression would not qualify as a "locking seal assembly," because there is no separate "locking" mechanism. The seal must incorporate a structural feature — such as a cam ring, a detent, a snap-fit tab, or the like — that affirmatively locks the seal into a fixed position.
This construction is grounded in the specification's own description of the invention, the prosecution history (where the applicant expressly disclaimed elastomeric compression seals in order to overcome a prior art rejection), and the ordinary meaning of "locking" in the mechanical engineering arts.
3. Apex's Proposed Construction
Based on the allegations in Apex's Complaint and Apex's interrogatory responses, we anticipate that Apex will propose a significantly broader construction along the lines of:
Any seal assembly capable of maintaining a sealed state during instrument passage, including by friction or compression.
Under Apex's anticipated construction, the word "locking" would be given a functional meaning — essentially equating "locking" with "maintaining" — such that any seal that stays in place during use would qualify. This construction would encompass conventional elastomeric compression seals, friction-fit seals, and any other seal that remains closed during instrument passage, regardless of whether a separate mechanical locking mechanism is present.
Apex will likely argue that "locking" is used in the claims as a descriptive adjective modifying "seal assembly" and should be read to describe the seal assembly's functional capability (maintaining a sealed state) rather than a specific structural feature (a mechanical lock). Apex may point to dictionary definitions of "lock" that include figurative or functional meanings, such as "to make fast or immovable" or "to fix firmly in a position."
4. Intrinsic Evidence Analysis
Specification. The specification of the '237 Patent provides robust support for Solstice's narrower construction. The detailed description devotes substantial attention to the mechanical locking mechanism, describing it as the distinguishing feature of the invention over the prior art. Specifically, the specification describes a "cam-actuated locking ring" as the mechanism by which the seal assembly is locked into position:
"The locking seal assembly 100 comprises a rotatable cam ring 110 disposed about the outer circumference of the seal housing 102. When the cam ring 110 is rotated from the unlocked position (FIG. 3A) to the locked position (FIG. 3C), cam surfaces 112a, 112b engage corresponding grooves 114a, 114b formed in the inner wall of the housing 104, thereby fixing the seal assembly in the closed, sealed position." (Col. 6, ll. 14–23.)
Figures 3A through 3C illustrate the sequential operation of the cam-actuated locking mechanism, showing the cam ring rotating from an unlocked position (where the seal can be opened or removed) to a locked position (where the cam surfaces engage the retaining grooves). This is the only locking mechanism described in the specification. No alternative locking mechanisms — and specifically no friction-based or compression-based mechanisms — are described as performing the "locking" function.
Critically, the specification expressly distinguishes the prior art by reference to the deficiency of elastomeric compression seals:
"Prior art trocar seal assemblies typically rely on elastomeric compression to maintain a seal around surgical instruments inserted through the cannula. However, such elastomeric compression seals are prone to intermittent loss of pneumoperitoneum when instruments of varying diameters are exchanged, particularly during extended procedures where the elastomeric material may undergo stress relaxation." (Col. 1, ll. 45–53.)
This passage directly establishes that the invention of the '237 Patent was developed to solve the problems associated with elastomeric compression seals. Reading "locking seal assembly" to encompass the very prior art that the specification identifies as deficient would be inconsistent with the specification's own characterization of the invention.
Prosecution History. The prosecution history provides even stronger support for Solstice's construction and creates prosecution history estoppel that precludes Apex from recapturing the breadth it disclaimed. During prosecution of the '237 Patent, the examiner initially rejected the original claims — which recited a "seal assembly" without the "locking" modifier — over U.S. Patent No. 7,235,063 to Chen and U.S. Patent No. 7,887,530 to Williams, both of which disclosed elastomeric compression seals for trocar assemblies.
In response, Dr. Szabo (through Apex's patent prosecution counsel at Kendrick & Lau LLP) amended independent Claim 1 to add the word "locking" before "seal assembly" and submitted a Response dated March 14, 2017, arguing:
"The claimed 'locking seal assembly' is patentably distinct from the seal assemblies of Chen and Williams, which rely solely on elastomeric compression to maintain a seal. The claimed locking seal assembly includes a distinct mechanical interlock — specifically, a cam-actuated locking ring engaging a retaining groove — that positively fixes the seal in the closed position. This is not merely a friction or compression seal, but a mechanical locking mechanism that affirmatively prevents seal displacement during instrument exchange." (March 14, 2017 Response at 8–9, emphasis added.)
This statement constitutes a clear and unambiguous disavowal of claim scope. By amending the claims to add "locking" and expressly arguing that the locking feature is a "distinct mechanical interlock, not merely a friction or compression seal," the applicant surrendered coverage of friction-fit and elastomeric compression seals. Under Festo Corp. v. Fenmore & Co., 535 U.S. 722, 733–34 (2002), and Norian Corp. v. Hollowell Industries, 363 F.3d 1321, 1332 (Fed. Cir. 2004), the prosecution history estoppel arising from a narrowing amendment bars the patentee from later recapturing the surrendered subject matter, whether literally or under the doctrine of equivalents.
5. Extrinsic Evidence
Dr. Miriam Ostrowski, Solstice's retained expert, has provided a preliminary analysis confirming that a person of ordinary skill in the art ("POSITA") in the field of minimally invasive surgical devices would understand "locking" to connote a positive mechanical engagement, not passive friction. Dr. Ostrowski notes that in the medical device engineering field, the term "locking" is universally understood to refer to a mechanism that physically restrains a component in a fixed position through positive mechanical engagement — such as a detent, cam, latch, or snap-fit — as distinguished from a "seal" or "sealing" mechanism that relies on material compression or friction. This distinction is consistent with standard references in mechanical engineering, including Shigley's Mechanical Engineering Design (11th ed.) and the ASM Handbook on Mechanical Fastening, Joining, and Assembly, both of which distinguish "locking" mechanisms (which involve positive mechanical engagement) from "sealing" mechanisms (which involve material deformation or interference fits).
Additionally, FDA guidance documents relating to laparoscopic trocar design (see FDA Draft Guidance for Industry, "Laparoscopic Trocar and Cannula Systems," January 2003) distinguish between "locking" mechanisms (which provide positive retention of components) and "sealing" mechanisms (which prevent gas leakage), further supporting the view that "locking" has a specific meaning distinct from "sealing" in this field.
6. Case Law Support
Several Federal Circuit decisions support the proposition that "locking" requires positive mechanical engagement rather than mere friction or resistance:
• Kara Tech., Inc. v. Stamps.com, Inc., 582 F.3d 1341, 1347 (Fed. Cir. 2009): The court construed "locking" to require a "positive engagement that prevents relative motion," distinguishing passive resistance or friction.
• Nystrom v. Larkspur Holdings, 424 F.3d 1136, 1144–45 (Fed. Cir. 2005): The court emphasized that where a specification consistently uses a term in a particular way and distinguishes prior art on that basis, the term should be construed consistently with the specification's usage.
• Omega Eng'g, Inc. v. Raytek Corp., 334 F.3d 1314, 1323–24 (Fed. Cir. 2003): Where the applicant distinguished prior art during prosecution by emphasizing a specific feature, the court held that the applicant had disclaimed the broader interpretation.
Chief Judge Andrews' own claim construction practice in the District of Delaware provides further support. In Arthrex, Inc. v. Smith & Nephew, Inc., No. 1:17-cv-01642-RGA (D. Del. Mar. 15, 2019), Chief Judge Andrews construed "locking" in the context of a surgical anchor to require "a mechanical interlock that positively prevents relative movement," rejecting the patentee's broader construction that would have encompassed friction-based retention. This ruling is directly analogous and provides strong precedent for our position.
7. Assessment of Likely Outcome
Strong position for Solstice. This is our strongest claim construction position. The prosecution history estoppel arising from the March 2017 amendment and response is dispositive. The applicant expressly disclaimed elastomeric compression seals and friction-fit seals by adding the word "locking" and arguing that the locking feature is a "distinct mechanical interlock." The specification independently supports this construction by describing the cam-actuated locking ring as the defining feature of the invention and by distinguishing prior art compression seals. The extrinsic evidence from Dr. Ostrowski and from standard technical references is consistent with, and reinforces, the intrinsic evidence.
Impact on Infringement Analysis. If the Court adopts Solstice's proposed construction (or any construction requiring a positive mechanical locking mechanism), the infringement case for the PE-5000 and PE-12000 Series with respect to the '237 Patent claims would be substantially undermined. The PrecisionEdge™ PE-5000 and PE-12000 products use Solstice's proprietary FlexSeal™ elastomeric compression seal — a silicone-based compression seal that creates a gas-tight seal through material deformation, without any separate mechanical locking ring, cam, detent, or other positive locking mechanism. Under Solstice's construction, the FlexSeal™ would not meet the "locking seal assembly" limitation, and Apex's infringement claims under the '237 Patent would fail as to both the PE-5000 and PE-12000 product lines.
B. Term 2: "retractable blade deployment mechanism" ('884 Patent, Claims 1, 2, 5, 9, 14)
1. Claim Language Context
The term "retractable blade deployment mechanism" appears in independent Claim 1 of the '884 Patent, which recites:
A trocar system comprising:
an obturator having a tissue-penetrating distal tip;
a retractable blade deployment mechanism housed within the obturator, the retractable blade deployment mechanism configured to deploy a cutting blade from a shielded position to an extended position for tissue penetration and to retract the cutting blade from the extended position to the shielded position;
a blade shield housing enclosing the retractable blade deployment mechanism and providing guide surfaces for blade travel; and
an actuating element configured to receive an actuating force applied by a user to initiate blade deployment.
The term is further limited by dependent Claims 2 (adding a "removably coupled" limitation), 5 (specifying structural details of the blade shield housing), 9 (specifying that the actuating force is "applied by a user"), and 14 (adding blade geometry limitations). The "retractable blade deployment mechanism" is the central inventive feature of the '884 Patent and appears in every asserted claim.
2. Solstice's Proposed Construction
Solstice proposes that "retractable blade deployment mechanism" be construed to mean:
A mechanism in which the blade is spring-loaded to extend for tissue penetration and automatically retracts into a shielded position upon release of the actuating force, the retraction being driven by a stored-energy element integral to the mechanism.
This construction limits the term in two important respects: (i) the retraction must be automatic (i.e., occurring upon release of the actuating force, without the need for a separate user action to initiate retraction), and (ii) the retraction must be driven by a stored-energy element (i.e., a spring or analogous energy-storage device) that is integral to the mechanism. Under this construction, a trocar with a blade that must be manually retracted by the user — or a blade retraction system that uses a motor, pneumatic actuator, or other non-stored-energy-element drive — would not fall within the claim scope.
3. Apex's Proposed Construction
We anticipate that Apex will propose:
Any mechanism capable of deploying a blade for penetration and thereafter retracting it, whether automatically or through manual user input.
Apex's construction reads "retractable" as a mere capability — the blade is "retractable" if it is capable of being retracted, regardless of how the retraction is accomplished. Under this reading, a trocar with a blade that the user manually pushes back into the shielded position after each use would satisfy the claim, as would a fully automatic spring-driven system.
4. Intrinsic Evidence Analysis
Specification. The specification of the '884 Patent describes a single mode of blade retraction throughout: automatic, spring-driven retraction. The specification states:
"The retractable blade deployment mechanism 200 utilizes a pre-loaded torsion spring 210 that stores energy when the blade 220 is in the shielded position. Upon application of actuating force by the user through the thumb actuator 230, the spring energy is redirected to deploy the blade 220 to the extended position. Upon release of the thumb actuator 230, the torsion spring 210 automatically retracts the blade 220 from the extended position to the shielded position, ensuring that the blade cutting edge is immediately shielded following tissue penetration." (Col. 5, ll. 22–38.)
This passage describes the complete operational cycle of the retractable blade deployment mechanism, and it is entirely automatic: the user presses the thumb actuator to deploy the blade, and the spring automatically retracts the blade when the actuator is released. There is no description anywhere in the specification of a manual retraction mode. Every embodiment disclosed in the specification — including the primary embodiment shown in Figures 5A–5D and the alternative embodiment described at Column 7, lines 10–45 (which substitutes a compression spring for a torsion spring) — utilizes automatic, spring-driven retraction.
Moreover, the specification expressly frames automatic retraction as a safety advantage over the prior art:
"Prior art trocar systems that require the user to manually retract the blade following tissue penetration present a significant safety risk, as the user may fail to retract the blade promptly or completely, potentially resulting in inadvertent tissue damage to underlying viscera or blood vessels." (Col. 2, ll. 8–16.)
This passage identifies manual blade retraction as a deficiency of the prior art — the very problem that the claimed "retractable blade deployment mechanism" was designed to solve. Reading the claim to encompass manual retraction systems would be inconsistent with the specification's characterization of manual retraction as a problem to be solved, not a solution.
Prosecution History. The prosecution history further supports a construction limited to automatic retraction, though the prosecution history record is somewhat less definitive than it is for Term 1. During prosecution, the examiner initially rejected the claims of the '884 Patent as anticipated under 35 U.S.C. § 102(a)(1) by U.S. Patent No. 6,478,773 to Gandhi, which disclosed a trocar with a blade that could be manually retracted by the user after tissue penetration.
In response, the applicant did not amend the claims but submitted a Response dated August 22, 2018, in which Dr. Szabo argued:
"The claimed retractable blade deployment mechanism is distinguishable from the Gandhi reference because Gandhi requires the surgeon to manually retract the blade after use. In contrast, the claimed mechanism provides automatic retraction upon release of the actuating force, driven by a stored-energy element (the pre-loaded torsion spring). This automatic retraction feature is a critical safety improvement that ensures immediate blade shielding upon completion of tissue penetration." (August 22, 2018 Response at 6.)
Following this Response, the examiner conducted a telephonic interview with Apex's prosecution counsel on September 10, 2018 (Interview Summary dated September 12, 2018), in which the examiner indicated that the distinction over Gandhi was persuasive and that the claims would be allowed if the applicant confirmed the automatic retraction feature. The applicant subsequently submitted a Supplemental Response confirming the distinction, and the claims were allowed.
While the applicant did not formally amend the claim language to add "automatic" or "spring-driven," the arguments made during prosecution — particularly the express distinction over a prior art reference with manual blade retraction — constitute a clear disavowal of manual retraction systems. Under Kestrel Partners LLC v. Multi-Tech Sys., Inc., 357 F.3d 1340, 1349 (Fed. Cir. 2004), arguments made during prosecution to distinguish prior art can narrow the scope of claims even absent a formal amendment.
5. Extrinsic Evidence
Dr. Ostrowski has confirmed that a POSITA in the field of laparoscopic trocar design would understand "retractable blade deployment mechanism" to refer to an automatic retraction system, consistent with the industry-standard safety paradigm for trocar blade mechanisms. Dr. Ostrowski notes that since the early 2000s, the medical device industry has moved overwhelmingly toward automatic blade retraction as the standard of care for trocar safety, and that the term "retractable" in the trocar context is universally understood to mean automatic retraction.
This understanding is consistent with FDA guidance documents on trocar blade safety. The FDA's 2003 Draft Guidance for Industry on "Laparoscopic Trocar and Cannula Systems" distinguishes between "retractable" blade mechanisms (which provide automatic shielding of the blade after tissue penetration) and "non-retractable" or "manually retractable" blade mechanisms, which require user intervention to shield the blade. The use of "retractable" without qualification in the claims, combined with the specification's exclusive focus on automatic retraction, strongly supports a construction limited to automatic retraction.
6. Case Law Support
The Federal Circuit has addressed the construction of terms where the specification discloses only a single mode of operation. In Glenrock Enterprises v. Adriatic Partners LLC, 242 F.3d 1337, 1341 (Fed. Cir. 2001), the court held that where the specification consistently describes the invention as having a particular feature, and the prosecution history reinforces this description, the claims should be construed to require that feature. The court explained that "[w]here the specification makes clear that the invention does not include a particular feature, that feature is not within the reach of the claim term." Similarly, in Honeywell Int'l, Inc. v. ITT Indus., Inc., 452 F.3d 1312, 1318 (Fed. Cir. 2006), the court held that where every disclosed embodiment includes a particular feature, and the specification distinguishes prior art based on the absence of that feature, the claim term should be construed to require that feature.
Chief Judge Andrews has applied these principles in his own claim construction practice. In Harborview Corporation, Inc. v. Boston Scientific Corp., No. 1:14-cv-01345-RGA (D. Del. June 22, 2016), Chief Judge Andrews construed "deployment mechanism" in the context of a cardiac stent to require the specific mode of operation disclosed in the specification, where the specification described only one mode and expressly distinguished prior art that used a different mode.
7. Assessment of Likely Outcome
Moderately strong position for Solstice. While the prosecution history is not as clean as it is for Term 1 (because the applicant did not formally amend the claim language), the combination of (i) the specification's exclusive disclosure of automatic, spring-driven retraction, (ii) the specification's express characterization of manual retraction as a deficiency of the prior art, and (iii) the prosecution history distinction over the Gandhi reference collectively present a strong case for a construction limited to automatic, spring-driven retraction. The principal risk is that Chief Judge Andrews may be reluctant to import a "spring-driven" limitation into the claims where the claim language does not expressly recite a spring, and may instead adopt a somewhat broader construction that requires automatic retraction but does not specify the drive mechanism. Even this intermediate construction, however, would be favorable to Solstice.
Impact on Infringement Analysis. This construction is critical for the PE-5000 non-infringement case. The PrecisionEdge™ PE-5000 uses a manually actuated, dual-stage retraction system in which the user first presses a deployment button to extend the blade and then manually actuates a separate retraction lever to retract the blade after tissue penetration. There is no stored-energy element (spring or otherwise) that automatically retracts the blade. Under Solstice's proposed construction, the PE-5000's dual-stage manual retraction system would not satisfy the "retractable blade deployment mechanism" limitation. Even under a broader construction that requires automatic retraction without specifying a spring, the PE-5000 would not infringe because its retraction is not automatic.
The PE-12000 and PE-15000 both use spring-loaded automatic retraction systems that are more closely aligned with the specification's described mechanism, so this construction has a more limited impact on those product lines. However, as discussed under Term 5 ("blade shield housing"), other structural differences may support non-infringement arguments for those products.
C. Term 3: "integrated insufflation valve" ('105 Patent, Claims 1, 4, 8)
1. Claim Language Context
The term "integrated insufflation valve" appears in independent Claim 1 of the '105 Patent, which recites:
A laparoscopic trocar comprising:
a trocar housing having a proximal end and a distal end;
an integrated insufflation valve disposed within the trocar housing, the integrated insufflation valve configured to selectively permit and restrict the flow of insufflation gas into the cannula lumen;
a gas-tight seal maintaining pneumoperitoneum during laparoscopic instrument exchange; and
a cannula extending distally from the trocar housing.
Dependent Claims 4 and 8 add further limitations: Claim 4 specifies that the trocar further comprises an "elastomeric sealing member," and Claim 8 adds structural limitations to the gas-tight seal.
2. Solstice's Proposed Construction
Solstice proposes:
A valve for controlling gas insufflation that is structurally incorporated as a unitary component within the trocar housing, rather than attached as a separate modular add-on.
The critical element of this construction is the requirement that the valve be "structurally incorporated as a unitary component" — i.e., that it be formed integrally with the housing rather than attached as a separate module. Under this construction, a trocar that uses a separately manufactured insufflation valve that is clipped, screwed, or otherwise attached to the exterior of the housing would not satisfy the limitation.
3. Apex's Proposed Construction
We anticipate that Apex will propose:
A valve for insufflation that is associated with the trocar assembly, whether formed integrally with or attached to the trocar housing.
Apex's construction treats "integrated" as a broad relational term — meaning merely that the valve is "part of" or "associated with" the trocar assembly — without requiring any particular mode of incorporation. Under this reading, a modular clip-on valve that is attached to the trocar housing would qualify as "integrated" simply because it is associated with the trocar.
4. Intrinsic Evidence Analysis
Specification. The specification of the '105 Patent uses "integrated" throughout to distinguish from prior art "modular" or "clip-on" insufflation valves. The specification states:
"In contrast to prior art trocar assemblies that utilize modular or clip-on insufflation valves, the integrated insufflation valve of the present invention is molded directly into the proximal housing, eliminating the potential for gas leakage at the valve-to-housing junction and reducing the total part count of the trocar assembly." (Col. 4, ll. 5–12.)
This passage directly contrasts "integrated" (molded directly into the housing) with "modular" or "clip-on" (attached as separate components), providing a clear definition-by-contrast that supports Solstice's construction. The specification further explains the advantages of integration — elimination of junction leakage and reduced part count — which are advantages that flow specifically from the unitary construction and would not be achieved by a modular add-on.
Additional passages in the specification consistently describe the insufflation valve as being "formed as part of" (Col. 5, l. 33), "integral with" (Col. 6, l. 8), and "unitarily constructed with" (Col. 7, l. 19) the trocar housing. No embodiment in the specification describes a valve that is separately manufactured and then attached to the housing.
Prosecution History. The prosecution history provides additional support. The claims of the '105 Patent as originally filed recited an "insufflation valve" without the "integrated" modifier. The examiner rejected the claims over U.S. Patent No. 8,114,121 to Park, which disclosed a trocar with a modular, snap-on insufflation valve. In response, the applicant amended the claims to add "integrated" and argued in a Response dated July 15, 2020:
"The claimed 'integrated insufflation valve' is structurally distinct from the modular valve of Park. The Park valve is a separately manufactured component that is snap-fitted onto the trocar housing. In contrast, the claimed integrated insufflation valve is formed as a unitary component within the trocar housing, as described in the specification at Column 4, lines 5–12." (July 15, 2020 Response at 5.)
This amendment and argument create prosecution history estoppel similar to that arising from the '237 Patent prosecution. The applicant added "integrated" to distinguish over a modular valve and argued that "integrated" means "formed as a unitary component within the trocar housing." Apex cannot now argue that "integrated" encompasses modular or clip-on valves.
5. Extrinsic Evidence
Standard engineering usage supports Solstice's construction. In the mechanical and biomedical engineering fields, "integrated" is consistently used to describe a component that is structurally incorporated into a larger assembly as a unitary element, as opposed to being separately manufactured and then attached. Dr. Ostrowski has confirmed that a POSITA would understand "integrated" in this sense.
The Sterling Reach Industries Dictionary of Scientific and Technical Terms (7th ed.) defines "integrated" in the relevant engineering context as "[c]ombined into or formed as a single unit," which is consistent with Solstice's construction.
6. Assessment of Likely Outcome
Moderate position for Solstice. The intrinsic evidence strongly favors Solstice's construction — the prosecution amendment and argument clearly distinguish modular valves, and the specification consistently describes the integrated valve as unitarily formed with the housing. We expect that the Court will adopt a construction requiring the valve to be formed as a unitary part of the housing rather than attached as a separate modular component.
However, the practical impact of this construction on the infringement analysis is more limited than for Terms 1 and 2. The PE-12000 and PE-15000 both feature insufflation valves that are arguably "integrated" into the housing in that they are insert-molded during the manufacturing process rather than being separately attached after assembly. While there is a factual dispute about whether the PE-12000 and PE-15000 valves are truly "unitary" with the housing (Solstice's engineering team has characterized the valves as separately manufactured inserts that are over-molded during the housing manufacturing process), the resolution of that dispute is a question of fact for infringement analysis, not a question of claim construction. Even under Solstice's proposed construction, the infringement analysis for Terms 3 remains fact-intensive with respect to the PE-12000 and PE-15000.
The primary value of a favorable construction on this term lies in its contribution to the invalidity analysis (a narrower claim is more likely to withstand invalidity challenges) and to the damages apportionment analysis (a narrower construction limits the scope of the patented feature to which damages may be attributed).
D. Term 4: "cannula having a proximal seal interface" ('237 Patent, Claims 1, 7)
1. Claim Language Context
The term "cannula having a proximal seal interface" appears in independent Claim 1 and dependent Claim 7 of the '237 Patent. As set forth in the Claim 1 excerpt above, this term describes the structural relationship between the cannula body and the seal assembly — specifically, the proximal end of the cannula where it connects to and interfaces with the seal assembly.
2. Solstice's Proposed Construction
Solstice proposes:
A cannula with a specifically configured proximal end that includes a machined or molded surface designed to mate with and receive a seal assembly through a defined mechanical interface (e.g., threads, bayonet, or snap-fit).
The key requirement of this construction is that the proximal end of the cannula must include a defined mechanical interface — a specifically configured surface that mates with the seal assembly through a defined coupling mechanism. Under Solstice's construction, a cannula that merely contacts a seal through an unstructured or incidental surface would not have a "proximal seal interface."
3. Apex's Proposed Construction
We anticipate that Apex will propose:
A cannula having any proximal region that contacts or is adjacent to a seal.
Apex's construction reads "interface" as synonymous with "area" or "region" — any part of the cannula that is near or in contact with a seal. This reading would render the word "interface" essentially meaningless, as every cannula that has a seal at its proximal end would inherently have a proximal region that contacts the seal.
4. Intrinsic Evidence Analysis
Specification. The specification of the '237 Patent describes three distinct embodiments of the "proximal seal interface": (i) a threaded interface in which the proximal end of the cannula includes external threads that engage internal threads on the seal housing (Col. 4, ll. 30–40; Fig. 2A); (ii) a bayonet-mount interface in which the proximal end includes radial pins that engage L-shaped slots on the seal housing (Col. 4, ll. 41–52; Fig. 2B); and (iii) a snap-fit interface in which the proximal end includes a circumferential ridge that snaps into a corresponding groove on the seal housing (Col. 4, ll. 53–62; Fig. 2C). In each embodiment, the "proximal seal interface" is a specifically configured surface feature — threads, pins, or a ridge — that provides a defined mechanical coupling between the cannula and the seal assembly.
No embodiment describes a smooth or unstructured proximal surface as constituting a "seal interface." The specification's consistent use of the term to describe defined mechanical coupling features supports the conclusion that "interface" requires more than mere proximity or incidental contact.
Prosecution History. There are no significant amendments or arguments in the prosecution history specifically directed at the term "cannula having a proximal seal interface." However, the absence of prosecution history narrowing does not undermine Solstice's position, because the specification itself provides sufficient context to construe the term.
Claim Construction Canons. Apex's overly broad construction would render the word "interface" superfluous. Under the principle of claim differentiation and the canon against surplusage, every word in a claim is presumed to have meaning. See Ashbury Enterprises v. Teva Pharms. USA, Inc., 395 F.3d 1364, 1372 (Fed. Cir. 2005). If "proximal seal interface" meant merely "proximal region that contacts or is adjacent to a seal," the word "interface" would add nothing to "proximal" — the claims could simply recite "a cannula having a proximal end adjacent to a seal." The addition of "interface" must carry independent meaning, and that meaning, informed by the specification, is a defined mechanical coupling structure.
5. Assessment of Likely Outcome
Favorable to Solstice. The specification's consistent description of three embodiments, all involving defined mechanical interfaces, provides strong support for a construction requiring a defined mechanical coupling feature. Apex's construction is untenable because it would render "interface" superfluous. Chief Judge Andrews has consistently applied the canon against surplusage in his claim construction rulings, and we expect he will do so here.
Impact on Infringement Analysis. The PE-5000 uses a smooth-bore press-fit connection between the cannula and the seal housing. The proximal end of the PE-5000 cannula does not include threads, bayonet pins, snap-fit ridges, or any other defined mechanical interface structure. Instead, the cannula is inserted into the seal housing and held in place by an interference fit between the smooth outer surface of the cannula and the smooth inner surface of the housing bore. Under Solstice's construction, this smooth-bore press-fit connection would not constitute a "proximal seal interface," and the PE-5000 would not satisfy this claim limitation.
The PE-12000 uses a threaded connection that more closely resembles the threaded interface embodiment in the specification, and the PE-15000 uses a bayonet-style connection. For these products, the "proximal seal interface" limitation is likely met even under Solstice's construction.
E. Term 5: "blade shield housing" ('884 Patent, Claims 1, 5, 14)
1. Claim Language Context
The term "blade shield housing" appears in independent Claim 1 and dependent Claims 5 and 14 of the '884 Patent. As set forth in the Claim 1 excerpt in Section IV.B above, the "blade shield housing" is described as "enclosing the retractable blade deployment mechanism and providing guide surfaces for blade travel." The term describes the structural housing that contains the blade, the blade retraction mechanism, and the movable shield that covers the blade's cutting edge when in the retracted position.
2. Solstice's Proposed Construction
Solstice proposes:
An enclosed housing structure that contains both the blade and a movable shield that covers the blade's cutting edge when in the retracted position.
This construction requires two features: (i) the housing must be an enclosed structure (not an open-frame or partial enclosure), and (ii) the housing must contain both the blade and a movable shield that covers the blade's cutting edge.
3. Apex's Proposed Construction
We anticipate that Apex will propose:
Any structure associated with the trocar tip that encloses or partially encloses the blade when not in use.
Apex's construction would encompass open-frame structures, partial enclosures, and any other structure that provides some degree of enclosure, without requiring that the structure be fully enclosed or that it include a movable shield.
4. Intrinsic Evidence Analysis
Specification. The specification of the '884 Patent describes the "blade shield housing" as a "self-contained enclosure" (Col. 4, l. 8) with specific structural features including internal guide rails for blade travel (Col. 4, ll. 12–18), a spring cavity for the torsion spring (Col. 4, ll. 19–24), and a shield stop that limits the travel of the movable shield (Col. 4, ll. 25–30). The specification further states:
"The blade shield housing 300 is a self-contained enclosure that fully encloses the retractable blade deployment mechanism, including the blade 220, the movable shield 310, and the torsion spring 210. The housing provides a sealed environment that prevents tissue or fluid intrusion into the blade mechanism during surgical use." (Col. 4, ll. 5–14.)
The use of "self-contained enclosure" and "fully encloses" strongly suggests that the housing must be a complete enclosure, not a partial or open-frame structure. The specification also describes the housing as "sealed" to prevent tissue or fluid intrusion, which would not be achievable with an open-frame structure.
Every embodiment in the specification shows the blade shield housing as a fully enclosed structure with specific internal features. Figures 5A through 5D show the housing as a closed cylindrical enclosure with internal guide rails and a spring cavity. The alternative embodiment described at Column 7, lines 10–45, similarly shows a fully enclosed housing.
Prosecution History. There are no significant amendments or arguments in the prosecution history specifically directed at the term "blade shield housing." However, the specification's consistent and detailed description of the housing as a "self-contained enclosure" with specific structural features provides adequate support for a construction requiring an enclosed structure.
5. Assessment of Likely Outcome
Favorable to Solstice. The specification's description of the blade shield housing as a "self-contained enclosure" that "fully encloses" the blade mechanism provides strong support for a construction requiring an enclosed (not merely partially enclosing) structure. While the absence of prosecution history narrowing on this term slightly reduces the strength of our position, the specification itself provides clear and consistent guidance.